Videos

Come celebrate the evolution of Psychiatric Times and psychiatry as a whole!

When prescribing ADHD medications, when is the best time to switch treatments?

Panelists discuss early signs of a positive response to treatment in postpartum depression (PPD), the specific symptoms to monitor, obstacles to accessing timely care in underserved populations, the role of family and community resources in recovery, key competencies for clinicians in addressing urgent PPD cases, and essential elements of a comprehensive, patient-centered treatment plan that balances medication, therapy, and support resources.

Panelists discuss the strategic decision-making process for choosing among selective serotonin reuptake inhibitors (SSRIs), rapid-onset treatments like zuranolone, and nonmedication therapies for postpartum depression (PPD), emphasizing the importance of treatment speed, severity of symptoms, and patient preferences.

How can we improve patient outcomes? Collaboration.

Ancillary symptoms may be key in guiding treatment management for ADHD.

Here are 4 things to do when implementing a treatment strategy for tardive dyskinesia.

Comorbid bipolar disorder and ADHD: a big problem.

Here's how to have productive conversations with patients with tardive dyskinesia in order to improve outcomes.

How can we get back to recovery as the treatment goal for schizophrenia?

2024 into 2025: a period of highs and lows for schizophrenia treatment.

Which came first: symptoms or diagnosis?

We're excited to preview our new upcoming partnership with the Psych NP Network at Real Psychiatry!

How has bipolar treatment changed over the past 40 years? The celebration of 40 years of Psychiatric Times continues at the Real Psychiatry conference.

Joseph Volpicelli MD, PhD, reflects on 40 years of advancements in addiction treatment, from overcoming stigma to integrating evidence-based therapies like naltrexone.

The top 3 issues in treating bipolar disorder are...

We've upgraded our phones and computers... is it time to upgrade our psychiatric medications?

Carmen Kosicek, MSN, PMHNP-BC, is ready to teach nurse practitioners and advanced providers in a fun, innovative way at Real Psychiatry in Scottsdale, AZ.

Want to stay in the loop on the latest novel neuroplastogen for major depressive disorder, DLX-001? Check out this update.

"In my poem, says another, I can forget I am forgotten. Now I understand being misunderstood..."

A patient discusses their struggles coming to terms with a posttraumatic stress disorder (PTSD) diagnosis after multiple traumatic events, detailing their initial resistance to seeking help, the breakthrough moments in therapy that led to acceptance, and their ongoing journey of healing through various treatment approaches.

Chris Schenewerk, MD, shares how his battle with alcohol addiction transformed his understanding of addiction treatment.

While current antidepressants are associated with improved lives for patients, significant challenges arise. Do we need a new class of antidepressants to address these issues?

How can personalized care, addressing comorbidities, and focusing on gradual improvement help increase treatment success for alcohol use disorder?

What can we learn from nonverbal cues?

Is there a way to separate the neuroplasticity and therapeutic effects from the hallucinatory and dissociative effects of traditional psychedelics?

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how effective screening tools like the Edinburgh Postnatal Depression Scale (EPDS) and PHQ-9, combined with comprehensive clinical assessments, are crucial for accurately identifying postpartum depression during routine prenatal and postnatal visits.

DLX-001 is a novel neuroplastogen under development for the treatment of major depressive disorder. Learn more about the latest phase 1 data here.

Panelists discuss how to diagnose postpartum depression (PPD) promptly using tools such as standardized screening questionnaires, especially in busy or resource-limited settings, and explore strategies to enhance PPD screening in underserved and minority populations in which symptoms may be underreported, while also considering the role of the case study patient’s family history in identifying her PPD symptoms.

Panelists discuss how specific symptoms, such as persistent sadness, emotional numbness, and disconnection from the baby, help distinguish postpartum depression (PPD) from postpartum anxiety or “baby blues,” and how to approach assessing a patient such as Emily, who is experiencing these symptoms for the first time despite previous pregnancies.